Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma
Papillary thyroid carcinoma (PTC) is the most frequent thyroid malignancy. Histopathological examination is widely accepted as the gold standard test for the diagnosis of PTC. However, the histopathological examination sometimes can't differentiate PTC from other thyroid diseases. Differentiati...
Gespeichert in:
| Veröffentlicht in: | Cancer biomarkers : section A of Disease markers 2024-01, Vol.39 (3), p.211-221 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 221 |
|---|---|
| container_issue | 3 |
| container_start_page | 211 |
| container_title | Cancer biomarkers : section A of Disease markers |
| container_volume | 39 |
| creator | Attia, Amany Selim Hussein, Samia Sameh, Hend Khalil, Amr Waley, Ahmad Barakat Matar, Ihab Sameh, Reham |
| description | Papillary thyroid carcinoma (PTC) is the most frequent thyroid malignancy. Histopathological examination is widely accepted as the gold standard test for the diagnosis of PTC. However, the histopathological examination sometimes can't differentiate PTC from other thyroid diseases. Differentiating PTC from other thyroid diseases is essential for a therapeutic approach and prognosis.
The current study was performed to investigate the utility of TROP-2, SPL-2, and CXCL12 mRNA and protein expression in discriminating PTC from other thyroid diseases that mimic PTC.
The current study was performed on 75 cases of surgically resected thyroid glands. The cases were distributed in two groups: the PTC group and the non-PTC group. The PTC group consisted of 35 cases (25 patients of the classic PTC variant and 10 patients of the PTC follicular variant). The non-PTC group consisted of 40 cases (10 cases were multinodular goiter, 5 cases were Graves' disease, 5 cases were Hashimoto thyroiditis, 15 patients were follicular adenoma (FA) and 5 cases were follicular carcinoma). TROP-2, SPL-2, and CXCL12 mRNA expression were estimated by qRT-PCR, and protein expression was estimated by immunohistochemistry.
There were upregulated TROP-2, SPL-2, and CXCL12 mRNA and protein expressions in PTC compared to non-PTC (P< 0.001, for each). There was a statistically significant upregulation in the mRNA expression of the three genes among PTC cases with larger tumor sizes (P< 0.001, for each), those with tumor stages III and IV (P= 0.008, 0.002 and < 0.001 respectively), and those with LN metastasis (P< 0.001, for each). Moreover, there was a statistically significant upregulation in CXCL-12 gene expression among PTC cases with extra-thyroid extension (P< 0.001).
mRNA expression of TROP-2, SPL-2, and CXCL12 among PTC cases increased in larger tumor size, tumor stages III and IV, and LN metastasis. Moreover, there was an increase in CXCL-12 gene expression among PTC cases with extra-thyroid extension. Thus, TROP-2, SPL-2, and CXCL12 expressions could be possible diagnostic and prognostic markers in PTC. |
| doi_str_mv | 10.3233/CBM-230230 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11091596</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2902939135</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-3d856fd6817e11775627b861bed8474ab9bd957465b675ded7c38c9c9f77f0353</originalsourceid><addsrcrecordid>eNpdkVtrFTEUhYMo9qIv_gAJ-CKlo7lMbk9FR2uFIxWt4FvIJJmelDnJmMyI59837WmLCoGdkI-112IB8AKjN5RQ-rZ7_6UhFNXzCOxjKVgjmSKP652JtkGY0T1wUMoVQi3FRD0Fe1QiQalQ-2D9IZjLmMocLDTRwSmn--cyhzHMW5gGePHt_GtDjuH31e24Abuf3QoT6P9M2ZcSUoQhwslMYRxN3sJ5vc0pOGhNtiGmjXkGngxmLP753TwEP04_XnRnzer80-fu3aqxlPO5oU4yPjgusfAYC8E4Eb3kuPdOtqI1veqdqrE467lgzjthqbTKqkGIAVFGD8HJTnda-o131sc5m1FPOWyqL51M0P_-xLDWl-m3xhgpzBSvCq_vFHL6tfgy600o1tdc0aelaKIQUVTh22Wv_kOv0pJjzacpwi0ivJW0Ukc7yuZUSvbDgxuM9E2Dujaodw1W-OXf_h_Q-8roNR1zlKk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3014026483</pqid></control><display><type>article</type><title>Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma</title><source>MEDLINE</source><source>Sage Journals GOLD Open Access 2024</source><creator>Attia, Amany Selim ; Hussein, Samia ; Sameh, Hend ; Khalil, Amr ; Waley, Ahmad Barakat ; Matar, Ihab ; Sameh, Reham</creator><creatorcontrib>Attia, Amany Selim ; Hussein, Samia ; Sameh, Hend ; Khalil, Amr ; Waley, Ahmad Barakat ; Matar, Ihab ; Sameh, Reham</creatorcontrib><description>Papillary thyroid carcinoma (PTC) is the most frequent thyroid malignancy. Histopathological examination is widely accepted as the gold standard test for the diagnosis of PTC. However, the histopathological examination sometimes can't differentiate PTC from other thyroid diseases. Differentiating PTC from other thyroid diseases is essential for a therapeutic approach and prognosis.
The current study was performed to investigate the utility of TROP-2, SPL-2, and CXCL12 mRNA and protein expression in discriminating PTC from other thyroid diseases that mimic PTC.
The current study was performed on 75 cases of surgically resected thyroid glands. The cases were distributed in two groups: the PTC group and the non-PTC group. The PTC group consisted of 35 cases (25 patients of the classic PTC variant and 10 patients of the PTC follicular variant). The non-PTC group consisted of 40 cases (10 cases were multinodular goiter, 5 cases were Graves' disease, 5 cases were Hashimoto thyroiditis, 15 patients were follicular adenoma (FA) and 5 cases were follicular carcinoma). TROP-2, SPL-2, and CXCL12 mRNA expression were estimated by qRT-PCR, and protein expression was estimated by immunohistochemistry.
There were upregulated TROP-2, SPL-2, and CXCL12 mRNA and protein expressions in PTC compared to non-PTC (P< 0.001, for each). There was a statistically significant upregulation in the mRNA expression of the three genes among PTC cases with larger tumor sizes (P< 0.001, for each), those with tumor stages III and IV (P= 0.008, 0.002 and < 0.001 respectively), and those with LN metastasis (P< 0.001, for each). Moreover, there was a statistically significant upregulation in CXCL-12 gene expression among PTC cases with extra-thyroid extension (P< 0.001).
mRNA expression of TROP-2, SPL-2, and CXCL12 among PTC cases increased in larger tumor size, tumor stages III and IV, and LN metastasis. Moreover, there was an increase in CXCL-12 gene expression among PTC cases with extra-thyroid extension. Thus, TROP-2, SPL-2, and CXCL12 expressions could be possible diagnostic and prognostic markers in PTC.</description><identifier>ISSN: 1574-0153</identifier><identifier>EISSN: 1875-8592</identifier><identifier>DOI: 10.3233/CBM-230230</identifier><identifier>PMID: 38073379</identifier><language>eng</language><publisher>Netherlands: IOS Press BV</publisher><subject>Carcinoma - diagnosis ; Carcinoma - genetics ; Carcinoma - pathology ; Carcinoma, Papillary ; Chemokine CXCL12 - genetics ; CXCL12 protein ; Diagnostic systems ; Gene expression ; Goiter ; Graves' disease ; Humans ; Immunohistochemistry ; Malignancy ; Metastases ; Metastasis ; Papillary thyroid carcinoma ; Prognosis ; Protein expression ; Proteins ; RNA, Messenger - genetics ; Statistical analysis ; Thyroid ; Thyroid cancer ; Thyroid Cancer, Papillary - diagnosis ; Thyroid Cancer, Papillary - genetics ; Thyroid diseases ; Thyroid Neoplasms - diagnosis ; Thyroid Neoplasms - genetics ; Thyroid Neoplasms - pathology ; Thyroiditis ; Tumors ; Up-regulation</subject><ispartof>Cancer biomarkers : section A of Disease markers, 2024-01, Vol.39 (3), p.211-221</ispartof><rights>Copyright IOS Press BV 2024</rights><rights>2024 – The authors. Published by IOS Press. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c366t-3d856fd6817e11775627b861bed8474ab9bd957465b675ded7c38c9c9f77f0353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38073379$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Attia, Amany Selim</creatorcontrib><creatorcontrib>Hussein, Samia</creatorcontrib><creatorcontrib>Sameh, Hend</creatorcontrib><creatorcontrib>Khalil, Amr</creatorcontrib><creatorcontrib>Waley, Ahmad Barakat</creatorcontrib><creatorcontrib>Matar, Ihab</creatorcontrib><creatorcontrib>Sameh, Reham</creatorcontrib><title>Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma</title><title>Cancer biomarkers : section A of Disease markers</title><addtitle>Cancer Biomark</addtitle><description>Papillary thyroid carcinoma (PTC) is the most frequent thyroid malignancy. Histopathological examination is widely accepted as the gold standard test for the diagnosis of PTC. However, the histopathological examination sometimes can't differentiate PTC from other thyroid diseases. Differentiating PTC from other thyroid diseases is essential for a therapeutic approach and prognosis.
The current study was performed to investigate the utility of TROP-2, SPL-2, and CXCL12 mRNA and protein expression in discriminating PTC from other thyroid diseases that mimic PTC.
The current study was performed on 75 cases of surgically resected thyroid glands. The cases were distributed in two groups: the PTC group and the non-PTC group. The PTC group consisted of 35 cases (25 patients of the classic PTC variant and 10 patients of the PTC follicular variant). The non-PTC group consisted of 40 cases (10 cases were multinodular goiter, 5 cases were Graves' disease, 5 cases were Hashimoto thyroiditis, 15 patients were follicular adenoma (FA) and 5 cases were follicular carcinoma). TROP-2, SPL-2, and CXCL12 mRNA expression were estimated by qRT-PCR, and protein expression was estimated by immunohistochemistry.
There were upregulated TROP-2, SPL-2, and CXCL12 mRNA and protein expressions in PTC compared to non-PTC (P< 0.001, for each). There was a statistically significant upregulation in the mRNA expression of the three genes among PTC cases with larger tumor sizes (P< 0.001, for each), those with tumor stages III and IV (P= 0.008, 0.002 and < 0.001 respectively), and those with LN metastasis (P< 0.001, for each). Moreover, there was a statistically significant upregulation in CXCL-12 gene expression among PTC cases with extra-thyroid extension (P< 0.001).
mRNA expression of TROP-2, SPL-2, and CXCL12 among PTC cases increased in larger tumor size, tumor stages III and IV, and LN metastasis. Moreover, there was an increase in CXCL-12 gene expression among PTC cases with extra-thyroid extension. Thus, TROP-2, SPL-2, and CXCL12 expressions could be possible diagnostic and prognostic markers in PTC.</description><subject>Carcinoma - diagnosis</subject><subject>Carcinoma - genetics</subject><subject>Carcinoma - pathology</subject><subject>Carcinoma, Papillary</subject><subject>Chemokine CXCL12 - genetics</subject><subject>CXCL12 protein</subject><subject>Diagnostic systems</subject><subject>Gene expression</subject><subject>Goiter</subject><subject>Graves' disease</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Malignancy</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Papillary thyroid carcinoma</subject><subject>Prognosis</subject><subject>Protein expression</subject><subject>Proteins</subject><subject>RNA, Messenger - genetics</subject><subject>Statistical analysis</subject><subject>Thyroid</subject><subject>Thyroid cancer</subject><subject>Thyroid Cancer, Papillary - diagnosis</subject><subject>Thyroid Cancer, Papillary - genetics</subject><subject>Thyroid diseases</subject><subject>Thyroid Neoplasms - diagnosis</subject><subject>Thyroid Neoplasms - genetics</subject><subject>Thyroid Neoplasms - pathology</subject><subject>Thyroiditis</subject><subject>Tumors</subject><subject>Up-regulation</subject><issn>1574-0153</issn><issn>1875-8592</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkVtrFTEUhYMo9qIv_gAJ-CKlo7lMbk9FR2uFIxWt4FvIJJmelDnJmMyI59837WmLCoGdkI-112IB8AKjN5RQ-rZ7_6UhFNXzCOxjKVgjmSKP652JtkGY0T1wUMoVQi3FRD0Fe1QiQalQ-2D9IZjLmMocLDTRwSmn--cyhzHMW5gGePHt_GtDjuH31e24Abuf3QoT6P9M2ZcSUoQhwslMYRxN3sJ5vc0pOGhNtiGmjXkGngxmLP753TwEP04_XnRnzer80-fu3aqxlPO5oU4yPjgusfAYC8E4Eb3kuPdOtqI1veqdqrE467lgzjthqbTKqkGIAVFGD8HJTnda-o131sc5m1FPOWyqL51M0P_-xLDWl-m3xhgpzBSvCq_vFHL6tfgy600o1tdc0aelaKIQUVTh22Wv_kOv0pJjzacpwi0ivJW0Ukc7yuZUSvbDgxuM9E2Dujaodw1W-OXf_h_Q-8roNR1zlKk</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Attia, Amany Selim</creator><creator>Hussein, Samia</creator><creator>Sameh, Hend</creator><creator>Khalil, Amr</creator><creator>Waley, Ahmad Barakat</creator><creator>Matar, Ihab</creator><creator>Sameh, Reham</creator><general>IOS Press BV</general><general>IOS Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240101</creationdate><title>Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma</title><author>Attia, Amany Selim ; Hussein, Samia ; Sameh, Hend ; Khalil, Amr ; Waley, Ahmad Barakat ; Matar, Ihab ; Sameh, Reham</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-3d856fd6817e11775627b861bed8474ab9bd957465b675ded7c38c9c9f77f0353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Carcinoma - diagnosis</topic><topic>Carcinoma - genetics</topic><topic>Carcinoma - pathology</topic><topic>Carcinoma, Papillary</topic><topic>Chemokine CXCL12 - genetics</topic><topic>CXCL12 protein</topic><topic>Diagnostic systems</topic><topic>Gene expression</topic><topic>Goiter</topic><topic>Graves' disease</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Malignancy</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Papillary thyroid carcinoma</topic><topic>Prognosis</topic><topic>Protein expression</topic><topic>Proteins</topic><topic>RNA, Messenger - genetics</topic><topic>Statistical analysis</topic><topic>Thyroid</topic><topic>Thyroid cancer</topic><topic>Thyroid Cancer, Papillary - diagnosis</topic><topic>Thyroid Cancer, Papillary - genetics</topic><topic>Thyroid diseases</topic><topic>Thyroid Neoplasms - diagnosis</topic><topic>Thyroid Neoplasms - genetics</topic><topic>Thyroid Neoplasms - pathology</topic><topic>Thyroiditis</topic><topic>Tumors</topic><topic>Up-regulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Attia, Amany Selim</creatorcontrib><creatorcontrib>Hussein, Samia</creatorcontrib><creatorcontrib>Sameh, Hend</creatorcontrib><creatorcontrib>Khalil, Amr</creatorcontrib><creatorcontrib>Waley, Ahmad Barakat</creatorcontrib><creatorcontrib>Matar, Ihab</creatorcontrib><creatorcontrib>Sameh, Reham</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer biomarkers : section A of Disease markers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Attia, Amany Selim</au><au>Hussein, Samia</au><au>Sameh, Hend</au><au>Khalil, Amr</au><au>Waley, Ahmad Barakat</au><au>Matar, Ihab</au><au>Sameh, Reham</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma</atitle><jtitle>Cancer biomarkers : section A of Disease markers</jtitle><addtitle>Cancer Biomark</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>39</volume><issue>3</issue><spage>211</spage><epage>221</epage><pages>211-221</pages><issn>1574-0153</issn><eissn>1875-8592</eissn><abstract>Papillary thyroid carcinoma (PTC) is the most frequent thyroid malignancy. Histopathological examination is widely accepted as the gold standard test for the diagnosis of PTC. However, the histopathological examination sometimes can't differentiate PTC from other thyroid diseases. Differentiating PTC from other thyroid diseases is essential for a therapeutic approach and prognosis.
The current study was performed to investigate the utility of TROP-2, SPL-2, and CXCL12 mRNA and protein expression in discriminating PTC from other thyroid diseases that mimic PTC.
The current study was performed on 75 cases of surgically resected thyroid glands. The cases were distributed in two groups: the PTC group and the non-PTC group. The PTC group consisted of 35 cases (25 patients of the classic PTC variant and 10 patients of the PTC follicular variant). The non-PTC group consisted of 40 cases (10 cases were multinodular goiter, 5 cases were Graves' disease, 5 cases were Hashimoto thyroiditis, 15 patients were follicular adenoma (FA) and 5 cases were follicular carcinoma). TROP-2, SPL-2, and CXCL12 mRNA expression were estimated by qRT-PCR, and protein expression was estimated by immunohistochemistry.
There were upregulated TROP-2, SPL-2, and CXCL12 mRNA and protein expressions in PTC compared to non-PTC (P< 0.001, for each). There was a statistically significant upregulation in the mRNA expression of the three genes among PTC cases with larger tumor sizes (P< 0.001, for each), those with tumor stages III and IV (P= 0.008, 0.002 and < 0.001 respectively), and those with LN metastasis (P< 0.001, for each). Moreover, there was a statistically significant upregulation in CXCL-12 gene expression among PTC cases with extra-thyroid extension (P< 0.001).
mRNA expression of TROP-2, SPL-2, and CXCL12 among PTC cases increased in larger tumor size, tumor stages III and IV, and LN metastasis. Moreover, there was an increase in CXCL-12 gene expression among PTC cases with extra-thyroid extension. Thus, TROP-2, SPL-2, and CXCL12 expressions could be possible diagnostic and prognostic markers in PTC.</abstract><cop>Netherlands</cop><pub>IOS Press BV</pub><pmid>38073379</pmid><doi>10.3233/CBM-230230</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1574-0153 |
| ispartof | Cancer biomarkers : section A of Disease markers, 2024-01, Vol.39 (3), p.211-221 |
| issn | 1574-0153 1875-8592 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11091596 |
| source | MEDLINE; Sage Journals GOLD Open Access 2024 |
| subjects | Carcinoma - diagnosis Carcinoma - genetics Carcinoma - pathology Carcinoma, Papillary Chemokine CXCL12 - genetics CXCL12 protein Diagnostic systems Gene expression Goiter Graves' disease Humans Immunohistochemistry Malignancy Metastases Metastasis Papillary thyroid carcinoma Prognosis Protein expression Proteins RNA, Messenger - genetics Statistical analysis Thyroid Thyroid cancer Thyroid Cancer, Papillary - diagnosis Thyroid Cancer, Papillary - genetics Thyroid diseases Thyroid Neoplasms - diagnosis Thyroid Neoplasms - genetics Thyroid Neoplasms - pathology Thyroiditis Tumors Up-regulation |
| title | Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T12%3A30%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnostic%20and%20prognostic%20utility%20of%20TROP-2,%20SLP-2,%20and%20CXCL12%20expression%20in%20papillary%20thyroid%20carcinoma&rft.jtitle=Cancer%20biomarkers%20:%20section%20A%20of%20Disease%20markers&rft.au=Attia,%20Amany%20Selim&rft.date=2024-01-01&rft.volume=39&rft.issue=3&rft.spage=211&rft.epage=221&rft.pages=211-221&rft.issn=1574-0153&rft.eissn=1875-8592&rft_id=info:doi/10.3233/CBM-230230&rft_dat=%3Cproquest_pubme%3E2902939135%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3014026483&rft_id=info:pmid/38073379&rfr_iscdi=true |